One-Day Ex Vivo Culture Allows Effective Gene Transfer Into Human Nonobese Diabetic/Severe Combined Immune-Deficient Repopulating Cells Using High-Titer Vesicular Stomatitis Virus G Protein Pseudotyped Retrovirus
Open Access
- 1 April 1999
- journal article
- Published by American Society of Hematology in Blood
- Vol. 93 (7) , 2217-2224
- https://doi.org/10.1182/blood.v93.7.2217
Abstract
Retrovirus-mediated gene transfer into long-lived human pluripotent hematopoietic stem cells (HSCs) is a widely sought but elusive goal. A major problem is the quiescent nature of most HSCs, with the perceived requirement for ex vivo prestimulation in cytokines to induce stem cell cycling and allow stable gene integration. However, ex vivo culture may impair stem cell function, and could explain the disappointing clinical results in many current gene transfer trials. To address this possibility, we examined the ex vivo survival of nonobese diabetic/severe combined immune-deficient (NOD/SCID) repopulating cells (SRCs) over 3 days. After 1 day of culture, the SRC number and proliferation declined twofold, and was further reduced by day 3; self-renewal was only detectable in noncultured cells. To determine if the period of ex vivo culture could be shortened, we used a vesicular stomatitis virus G protein (VSV-G) pseudotyped retrovirus vector that was concentrated to high titer. The results showed that gene transfer rates were similar without or with 48 hours prestimulation. Thus, the use of high-titer VSV-G pseudotyped retrovirus may minimize the loss of HSCs during culture, because efficient gene transfer can be obtained without the need for extended ex vivo culture.Keywords
This publication has 54 references indexed in Scilit:
- Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapyNature Medicine, 1996
- Gene-marking and haemopoietic stem-cell transplantationBlood Reviews, 1995
- T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 YearsScience, 1995
- Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA − Immunodeficient PatientsScience, 1995
- Pseudotyped retroviral vectors for studies of human gene therapyNature Medicine, 1995
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993
- Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures.Journal of Clinical Investigation, 1992
- Effects of transplantation on the primitive immunohematopoietic stem cell.The Journal of Experimental Medicine, 1990
- Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells.Proceedings of the National Academy of Sciences, 1989
- Engraftment of Immune-Deficient Mice with Human Hematopoietic Stem CellsScience, 1988